ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
High-Grade Immune-Related Adverse Events Resulting from Immune Checkpoint Inhibitor Treatment: Evaluation of Diagnostics and Outcomes in Admitted Patients.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a risk for immune-related adverse events (IRAEs), which can be life-threatening and limit further treatment when severe. The diagnostic evaluation and management of severe IRAEs, including steroid-refractory toxicity, remains challenging. This study aims to characterize severe IRAEs (grade 3 or higher) requiring inpatient management, including toxicity grading, diagnostic evaluation, and clinical outcomes.
methodsThis single center retrospective case-review analyzed 44 patients admitted due to IRAEs. Primary cancer, toxicity grade, ICI rechallenge, lab diagnostics, and outcomes including mortality, time to treatment, additional immunomodulating agent treatment, and length of stay were evaluated.
results44 patients with a total of 59 distinct IRAEs were analyzed. The median time to toxicity following ICI initiation was 18.5 weeks. The most common organ toxicities observed were colitis (n = 14), myocarditis (n = 12), and pneumonitis (n = 10) with a mean grade of 3.6. Mean time to corticosteroid treatment was 48.3 h; average length of stay was 12.2 days. Nearly one-third (31.8%) required management with immunomodulating agents in addition to corticosteroids. The most frequently elevated biomarkers were interleukin (IL)-10 (100%), C-reactive protein (CRP) (95.5%), CD25 (88.9%), and IL-6 (75%). IRAE-specific mortality was 22.7%.
conclusionPatients admitted for IRAEs tended to have high-grade toxicity and high mortality rates, highlighting the need for timely diagnostics and treatment. A cytokine signature of elevated CRP, CD25, IL-10, and IL-6 was identified and associated with IRAEs.
Indexed as
Identifiers
41711961What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.